Previous 10 | Next 10 |
2023-09-07 07:56:40 ET More on CymaBay Seeking Alpha’s Quant Rating on CymaBay Therapeutics Historical earnings data for CymaBay Therapeutics Financial information for CymaBay Therapeutics CymaBay Therapeutics, Inc. ( CBAY ) Q2 2023 Earnings Call...
2023-08-14 16:31:43 ET UBS has initiated coverage of Cymabay Therapeutics ( NASDAQ: CBAY ) with a buy rating, stating it sees a Phase 3 study for the company’s drug seladelpar in the treatment of primary biliary cholangitis, or PBC, yielding positive data. UBS said it exp...
2023-07-13 08:04:34 ET Intercept Pharmaceuticals ( NASDAQ: ICPT ) gained ~10% pre-market Thursday after H.C. Wainwright upgraded it to Buy from Sell, citing a novel drug combination the company is developing for an autoimmune disease called primary biliary cholangitis (PBC). ...
2023-07-03 08:41:08 ET PainReform ( PRFX ) +22% . Alvotech ( ALVO ) +19% . Ensysce Biosciences ( ENSC ) +12% . Alliance Entertainment ( AENT ) +10% . Great Ajax AJX +9% on plans to be acquired by Ellington Financial for $7.33...
2023-06-30 06:58:14 ET French biotech Genfit S.A. ( NASDAQ: GNFT ) added ~23% pre-market Friday after the company and its partner Ipsen ( OTCPK:IPSEY ) ( OTCPK:IPSEF ) announced that a Phase 3 trial for elafibranor targeted at the rare liver disease primary biliary chola...
2023-06-28 10:09:16 ET Gainers: Minerva Neurosciences ( NERV ) +51% . Regional Health Properties ( RHE ) +12% . Genfit ( GNFT ) +11% . RenovoRx ( RNXT ) +11% . OPKO Health ( OPK ) +5% . Losers: Cognition Therapeutics ( C...
2023-06-27 13:03:37 ET Biopharmaceutical firms focused on liver diseases trended lower Tuesday after pharma giant Eli Lilly ( NYSE: LLY ) announced data highlighting the potential of its weight loss candidate retatrutide in obese patients with excess liver fat. The condition kno...
Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF) PR Newswire Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical,...
2023-05-29 15:00:00 ET The Institute for Clinical and Economic Review (ICER), the influential U.S. drug pricing watchdog, has warned about the affordability of two medications currently undergoing studies for liver disease, nonalcoholic steatohepatitis (NASH). Issuing a so-called access...
2023-05-11 16:04:46 ET Summary Results from the phase 3 ELATIVE study, using elafibranor to treat patients with primary biliary cholangitis, are expected to be released before end of Q2 of 2023. The primary biliary cholangitis market is expected to reach $1.7 billion by 2029. ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-11 09:30:02 ET H.C. Wainwright analyst issues BUY recommendation for GNFT on June 11, 2024 07:43AM ET. The previous analyst recommendation was Buy. GNFT was trading at $5.535 at issue of the analyst recommendation. Historical Analyst Recommendations Latest ...
Lakeland Industries Inc. (LAKE) is expected to report $0.3 for Q4 2024 Sekisui House Ltd. ADR (SKHSY) is expected to report for Q4 2024 Hingham Institution for Savings (HIFS) is expected to report for Q1 2024 GENFIT S.A. (GNFT) is expected to report for Q4 2023 Jewett-Cameron Trad...
Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF) PR Newswire Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical,...